Connect with us

Company News

Neuronetics draws down remaining $22.5M available under credit facility

Neuronetics, Inc. announced that it has drawn down the remaining $22.5 million from its credit facility with SLR Capital Partners, LLC.

“We are pleased to have successfully drawn down the remaining capital as part of our credit facility with SLR, which further bolsters our balance sheet in a non-dilutive manner and will support the ongoing execution of our strategy,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics. “Given the current challenging equity and debt capital markets environment, we felt it was prudent to strengthen our balance sheet in a cost-effective manner. The Company continues to believe that it can attain self-sustainability with the previous cash balance and that it can achieve cash flow break-even in Q4-2024 and on a full-year basis in 2025. This incremental capital should remove any doubt about the Company needing to access the equity markets. I want to thank SLR for their continued support of our vision to advance neurohealth therapies and drive the further adoption of NeuroStar Advanced Therapy for mental health.”

In April 2023, the Company amended its senior secured credit facilities with SLR, securing up to $60.0 million in borrowings. This facility includes three tranches of term loans, consisting of a “Term A Loan” of $35.0 million, a “Term B Loan” of $2.5 million, and a “Term C Loan” of $22.5 million. The Company has drawn down all $60.0 million available as part of this credit facility and the maturity date of the $60 million facility is now set for March 29, 2028.
MB Bureau

Copyright © 2024 Medical Buyer

error: Content is protected !!